GET DAILY SIGNALSBioMarin Pharmaceutical (BMRN) Prepares for Q3 2026 Earnings with Amicus Integration in Focus
Key Takeaways
- BioMarin Pharmaceutical is scheduled to report third quarter 2026 results after the market close on Monday, November 2, 2026, with a conference call at 4:30 p.m. ET.
- Analysts expect non-GAAP earnings per share (EPS) of roughly $1.35 and total revenues of about $1.02 billion to $1.03 billion, which would mark a year-over-year revenue increase of more than 30%.
- The quarter is the first to include a full three months of contribution from the recently acquired Amicus products, GALAFOLD and POMBILITI + OPFOLDA.
- Management guided third quarter revenue slightly above the second quarter's $989.7 million and non-GAAP EPS slightly above the $1.20 reported in the prior period.
- Investors are closely watching VOXZOGO's competitive position following the U.S. launch of a rival therapy, with about 90% of U.S. patients remaining on treatment through the end of July.
- A roughly $283 million research and development (R&D) charge tied to the Alesta acquisition is expected to weigh on third quarter GAAP results, making the non-GAAP comparison especially important.
Why This Earnings Report Matters
BioMarin Pharmaceutical's third quarter report serves as an important checkpoint. The company completed its $4.8 billion acquisition of Amicus Therapeutics earlier in 2026, bringing in GALAFOLD for Fabry disease and POMBILITI + OPFOLDA for Pompe disease to complement its key growth driver, VOXZOGO. This marks the first full quarter with those additions, providing a clearer picture of the deal's revenue impact and potential synergies. At the same time, VOXZOGO is facing its initial real competition in the United States. After raising full-year guidance following a solid second quarter, the report will help assess whether that momentum holds.
What Analysts Are Expecting
Consensus estimates call for non-GAAP diluted EPS of about $1.35 and revenues in the $1.02 billion to $1.03 billion range for the third quarter of 2026. That would represent growth of roughly 30% or more year over year. Differences across estimates often stem from how one-time items are handled, including the $283 million R&D charge linked to the Alesta acquisition, which hits GAAP results but is excluded from non-GAAP measures.
Management has indicated that third quarter revenue should come in slightly above the second quarter's $989.7 million, supported by a full quarter of Amicus contributions and ongoing patient growth, with non-GAAP EPS expected to edge above the prior quarter's $1.20. The full-year 2026 outlook remains $3.875 billion to $3.925 billion in revenue and $4.90 to $5.10 in non-GAAP diluted EPS.
BioMarin has a track record of beating EPS estimates in most recent quarters, including a 25% surprise last quarter when it delivered $1.20 versus the $0.95 consensus. Still, the stock has moved lower since that August report, so this quarter's results and any updated guidance will be closely watched for signs of sentiment shift. I also checked this using Tickeron's AI Screener to see how the stock compares to others in the industry.
Current Sentiment and Market Reaction
Heading into the report, sentiment appears cautiously optimistic but mixed. BMRN holds a consensus "Moderate Buy" rating with average price targets well above recent trading levels, and several firms have raised targets or issued upgrades recently. At the same time, shares have lagged since the last earnings, reflecting questions around VOXZOGO competition and the Amicus integration. Key risks include the pace of any patient shifts to the competing therapy, near-term dilution and interest costs from acquisition debt, and the impact of one-time charges.
What to Watch Going Forward
Beyond the headline figures, several areas will shape the outlook for the rest of 2026 and into 2027. The VOXZOGO franchise stands out first: full-year guidance was raised to $1.00 billion to $1.05 billion, positioning it as BioMarin's potential first billion-dollar product. With about 90% of U.S. patients still on therapy despite the new competitor, the focus will be on whether switching stabilizes or picks up.
Next comes the Amicus integration. Management has targeted around $220 million in annual cost synergies by 2028 and expects the deal to be modestly dilutive in 2026 before turning accretive in 2027. Updates on synergy timing and growth for GALAFOLD and POMBILITI + OPFOLDA will draw attention.
Finally, the regulatory calendar includes a patent case before the International Trade Commission related to VOXZOGO, with a decision expected near year-end, plus progress on the supplemental New Drug Application for VOXZOGO in hypochondroplasia. Quarterly order-timing effects in the enzyme therapy portfolio can also add volatility to individual product revenues.
Using AI Tools in My Research
I frequently rely on Tickeron's AI Screener when preparing for earnings like this one. It helps me quickly filter stocks by technical patterns, fundamentals, and industry trends, which adds useful context when comparing BMRN to peers in rare-disease biotech.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
BMRN's RSI Indicator ascends from oversold territory
The RSI Oscillator for BMRN moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 30 similar instances when the indicator left oversold territory. In 23 of the 30 cases the stock moved higher. This puts the odds of a move higher at 77%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 43 of 62 cases where BMRN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 69%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on BMRN as a result. In 53 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.
The Moving Average Convergence Divergence (MACD) for BMRN just turned positive on October 20, 2026. Looking at past instances where BMRN's MACD turned positive, the stock continued to rise in 30 of 50 cases over the following month. The odds of a continued upward trend are 60%.
Following a +3.07% 3-day Advance, the price is estimated to grow further. Considering data from situations where BMRN advanced for three days, in 166 of 282 cases, the price rose further within the following month. The odds of a continued upward trend are 59%.
BMRN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
BMRN moved below its 50-day moving average on September 22, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BMRN crossed bearishly below the 50-day moving average on September 25, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 50%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMRN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.
The Aroon Indicator for BMRN entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. BMRN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 89 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.707) is normal, around the industry mean (3.035). BMRN's P/E Ratio (150.676) is considerably higher than the industry average of (-1.360). Projected Growth (PEG Ratio) (0.348) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (3.727) is also within normal values, averaging (438.009).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMRN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of innovative pharmaceuticals for serious diseases & medical conditions
Industry Biotechnology
Advertisement